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Abstract
Background
Malaria in pregnancy is associated with adverse birth outcomes. However, the underlying
mechanisms remain poorly understood. Tight regulation of angiogenic, metabolic, and
inflammatory pathways are essential for healthy pregnancies. We hypothesized that malaria
disrupts these pathways leading to preterm birth (PTB).
Methods and findings
We conducted a secondary analysis of a randomized trial of malaria prevention in preg-
nancy conducted in Malawi from July 21, 2011, to March 18, 2013. We longitudinally
assessed circulating mediators of angiogenic, metabolic, and inflammatory pathways during
pregnancy in a cohort of HIV-negative women (n = 1,628), with a median age of 21 years
[18, 25], and 562 (35%) were primigravid. Pregnancies were ultrasound dated, and samples
were analyzed at 13 to 23 weeks (Visit 1), 28 to 33 weeks (Visit 2), and/or 34 to 36 weeks
(Visit 3). Malaria prevalence was high; 70% (n = 1,138) had PCR-positive Plasmodium fal-
ciparum infection at least once over the course of pregnancy and/or positive placental histol-
ogy. The risk of delivering preterm in the entire cohort was 20% (n = 304/1506). Women with
malaria before 24 weeks gestation had a higher risk of PTB (24% versus 18%, p = 0.005;
adjusted relative risk [aRR] 1.30, 95% confidence interval [CI] 1.04–1.63, p = 0.021); and
those who were malaria positive only before week 24 had an even greater risk of PTB (28%
versus 17%, p = 0.02; with an aRR of 1.67, 95% CI 1.20–2.30, p = 0.002). Using linear
mixed-effects modeling, malaria before 24 weeks gestation was associated with altered
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kinetics of inflammatory (C-Reactive Protein [CRP], Chitinase 3-like protein-1 [CHI3L1],
Interleukin 18 Binding Protein [IL-18BP], soluble Tumor Necrosis Factor receptor II
[sTNFRII], soluble Intercellular Adhesion Molecule-1 [sICAM-1]), angiogenic (soluble Endo-
glin [sEng]), and metabolic mediators (Leptin, Angiopoietin-like 3 [Angptl3]) over the course
of pregnancy (χ2 > 13.0, p� 0.001 for each). Limitations include being underpowered to
assess the impact on nonviable births, being unable to assess women who had not received
any antimalarials, and, because of the exposure to antimalarials in the second trimester,
there were limited numbers of malaria infections late in pregnancy.
Conclusions
Current interventions for the prevention of malaria in pregnancy are initiated at the first ante-
natal visit, usually in the second trimester. In this study, we found that many women are
already malaria-infected by their first visit. Malaria infection before 24 weeks gestation was
associated with dysregulation of essential regulators of angiogenesis, metabolism, and
inflammation and an increased risk of PTB. Preventing malaria earlier in pregnancy may
reduce placental dysfunction and thereby improve birth outcomes in malaria-endemic
settings.
Author summary
Why was this study done?
• Malaria infection during pregnancy has serious consequences for the mother and her
unborn child.
• We have a poor understanding of the mechanisms by which malaria causes adverse
birth outcomes, especially preterm birth (PTB), a leading cause of death in children less
than 5 years of age.
• Efforts to date to prevent malaria in pregnant women have not been shown to reduce
the risk of PTB associated with malaria infection.
• We conducted this study to assess if malaria infection, especially early in pregnancy,
might alter important factors that control placental growth and function and determine
if these lead to PTB.
What did the researchers do and find?
• We measured levels of 10 different angiogenic, inflammatory, and/or metabolic proteins
longitudinally during pregnancy in a large cohort of 1,628 Malawian women at risk of
malaria infection and demonstrate that early infection with malaria is associated with
changes in several key proteins that are important for healthy pregnancies.
• The use of ultrasound dating highlighted the contribution of early malaria infection to
an increased risk of delivering preterm, previously thought to occur primarily from
malaria late in pregnancy.
Early malaria infection and risk of preterm birth
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What do these findings mean?
• Current interventions to prevent malaria in pregnancy are usually initiated at the first
antenatal visit in the second trimester.
• This study demonstrates that many women are already malaria-infected at this first visit
and that these early infections are sufficient to alter factors essential for the placenta to
adequately support fetal growth and healthy pregnancy outcomes.
• These early infections increase the risk of delivering preterm, indicating that interven-
tions to prevent malaria in pregnancy may need to be started earlier in pregnancy in
order to reduce malaria-associated adverse birth outcomes.
Introduction
In sub-Saharan Africa, an estimated 28 million women were at risk of malaria in pregnancy
(MIP) in 2014 [1]. MIP is associated with adverse birth outcomes, including preterm birth
(PTB), fetal growth restriction (FGR), and stillbirth [2–4]. However, our understanding of the
underlying mechanisms is limited [2]. Low birth weight (LBW) infants, including those caused
by PTB and those born small for gestational age (SGA), are at increased risk of death during
infancy with the risk extending to all-cause mortality in adulthood [5–7]. Furthermore, LBW
infants are at increased risk of developing chronic illnesses, including diabetes, hypertension,
cancer, and neuropsychiatric disorders [5,8,9].
The timing of MIP may influence the risk and type of adverse birth outcome. The risk of
FGR appears to be higher in women with antenatal malaria earlier in pregnancy [10–14]. In
contrast, women with PTB are reported to be at higher risk if they had malaria later in preg-
nancy [13,14], including at delivery [10,11]. However, mechanistically, it is unclear how the
timing of MIP differentially impacts birth outcomes.
Following red-cell invasion, the parasite expresses Plasmodium falciparum erythrocyte
membrane protein 1 (PfEMP1) on the surface of the infected erythrocyte. During pregnancy, a
PfEMP1 variant encoded by var2csa mediates adhesion of the infected erythrocyte to chondroi-
tin sulphate A and enables it to sequester within the placental intervillous space, contributing
to inflammatory infiltrates and reduced nutrient transfer to the fetus [2,15]. Using a combina-
tion of structure equation modeling and in vivo models of MIP, Conroy and colleagues showed
that monocytic infiltration contributes to complement activation and subsequent dysregulation
of angiogenic factors, such as soluble Endoglin (sEng), that are essential for placental angiogen-
esis and vascular remodeling [16]. Although a detailed understanding of the mechanisms
underlying malaria-associated adverse birth outcomes is lacking, the available evidence indi-
cates that malaria infection may alter placental vascular development as evidenced by increased
placental vascular resistance and micro-CT imaging of placental vasculature in human studies
and preclinical models, respectively [16–24]. Previous pregnancy studies have shown that alter-
ations in angiogenic and inflammatory mediators are associated with adverse birth outcomes
at delivery [18,19,25]. However, these observations need to be evaluated over the course of
pregnancy in a large cohort of women with high levels of malaria exposure.
We hypothesize that malaria early in pregnancy results in the dysregulation of inflamma-
tory and angiogenic pathways resulting in placental insufficiency and adverse birth outcomes.
To test this hypothesis, our objective was to longitudinally characterize circulating levels of
Early malaria infection and risk of preterm birth
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angiogenic, metabolic, and inflammatory mediators over the course of pregnancy in a large
cohort of Malawian women in an area with moderate to intense malaria transmission and
assess the association of malaria infection with adverse birth outcomes.
Methods
Study population and trial design
This study cohort was nested within a randomized clinical trial of MIP prevention in Malawi.
Briefly, HIV-negative women enrolled from July 21, 2011, to March 18, 2013 were randomized
to intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine
(SP), the standard of care, or intermittent screening and treatment in pregnancy (ISTp) with
dihydroartemisinin-piperaquine (DP) [26].
Participants were eligible for inclusion in the trial if they were HIV negative, singleton preg-
nancies, agreed to deliver in a local health facility, hemoglobin>70 g/L, and had not previously
received IPTp-SP [26]. Participants were eligible for the present study if they were enrolled
<24 weeks of gestation, and had frozen plasma samples for testing from one or more of the fol-
lowing gestational ages: 13 to 23 weeks (Visit 1), 28 to 33 weeks (Visit 2), 34 to 36 weeks (Visit
3). The study size was determined based on availability of samples from the parent trial. Partic-
ipants were excluded if no plasma samples were available for testing or if there were no PCR or
placental histology data available. All women were provided with an insecticide-treated bed
net at their enrolment visit.
The ultrasound dating was performed during the second trimester on a Sonosite S180 por-
table ultrasound scans (Sonosite, Bothell, Washington) by M. Madanitsa and research nurses
as described by Wylie and colleagues [27]. The estimated gestational age was calculated by the
Hadlock formula. The majority of deliveries were either spontaneous or assisted (by vacuum
or forceps); however, there were a small number of deliveries performed by C-section. No data
were available on inductions or indications for C-sections in this cohort.
This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guideline (S1 STROBE Checklist). All methods of assessment were
similar across groups, and malaria status and birth outcomes were unknown to the individuals
performing the mediator assays.
Plasma marker testing
Angiogenic, inflammatory, and metabolic factors tested were selected based on previous stud-
ies [18,19,25]. Luminex multiplex assays or ELISAs were used to measure plasma factor con-
centrations (R&D Systems. Minneapolis, MN; S1 Table). The following mediators were tested
by Luminex assays: Leptin, sEng, Placental Growth Factor (PlGF), and soluble Fms-like Tyro-
sine Kinase-1 (sFlt-1/soluble VEGFR1; Custom kit); soluble Intercellular Adhesion Molecule-1
(sICAM-1), Angiopoietin-like 3 (Angptl3), Chitinase 3-like protein-1 (CHI3L1), and soluble
Tumor Necrosis Factor receptor II (sTNFRII; Kit # LXSAHM-5). Data were collected using
xPONENT version 4.2 software on a Luminex MagPix machine (Luminex, Toronto, Canada).
ELISAs were used to measure C-Reactive Protein (CRP) and Interleukin 18 Binding Protein
(IL-18BP; DuoSet ELISA Kits), modified protocol as previously reported by Conroy and col-
leagues [28].
Definitions
Adverse birth outcomes were defined as LBW (birth weight <2,500g), PTB (<37 weeks gesta-
tional age based on ultrasound dating, completed during the second trimester), SGA (<10th
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percentile for gestational age using Intergrowth 21st Standards [29]), and nonviable births
(either stillbirth [>28 weeks] or spontaneous abortion [<28 weeks]). PTB, LBW, and SGA
were dichotomous variables based on standard clinical case definitions as above [4]. Educa-
tional status was defined by years of schooling: low (<5), medium (5 to<10), or high (�10).
Socioeconomic status was defined in tertiles using principal component analysis based on a
survey including various household assets and characteristics. Socioeconomic status and edu-
cational status were kept continuous when adjusted for in multivariate and/or multivariable
models. Data on rates of preeclampsia were unavailable for this cohort. Malaria status was
assessed using real-time PCR during pregnancy, and histology and/or PCR at delivery; the
real-time PCR assay used targeted both the parasite gene pfldh and the human gene beta-tubu-
lin as an internal control. PCR detection was completed for specimens from scheduled visits
(up to 5 throughout pregnancy: 13–23 weeks, 24–27 weeks, 28–33 weeks, 34–36 weeks, and at
delivery) and from any unscheduled sick visits, up to 8 visits for some women [26]. Malaria-
negative women were defined as women without any recorded positive PCR samples during
pregnancy and were negative for malaria by placental histology. Women were defined as “any
malaria positive” if they had any malaria-positive PCRs and/or malaria-positive placental
histology.
Ethics
This study was approved by the Liverpool School of Tropical Medicine, the Malawian National
Health Science Research Committee, and the University Health Network Research Ethics
Committee of the University of Toronto. Written informed consent was obtained for all
study participants. The larger trial was registered: Pan African Clinical Trials Registry
PACTR201103000280319; ISRCTN Registry ISRCTN69800930.
Statistical analysis
Statistical analysis was conducted using GraphPad Prism 7, IBM SPSS Statistics 24, and R ver-
sion 3.5.1 (R Core Team, 2018). A prospective protocol for analysis was not prepared for this
study; however, the statistical approach described below was decided prior to commencement
of analysis and was based on publications analyzing similar longitudinal data [22,30]. Compar-
ison between continuous variables was done by Mann-Whitney analysis, and comparison
between categorical variables was done by Chi-square analysis. For marker comparison based
on malaria status at each visit, an adjusted p� 0.005 was used to correct for multiple compari-
sons. Relative risk (RR) and corresponding 95% confidence intervals (CIs) of adverse birth
outcomes based on malaria status were calculated using log-binomial regression with a log
link function. We used multivariable quantile regression to further assess the effect of malaria
infection on gestational age at delivery. Multivariable models were adjusted for treatment arm
(ISTp versus IPTp), maternal age, gravidity, socioeconomic status, education status, body
mass index (BMI), and hemoglobin at Visit 1. Adjusters were included in multivariable analy-
ses based on an a priori hypothesized relationship with the outcome of interest and were fur-
ther considered if they had a p< 0.05 in bivariate analysis (Table 1). No variables chosen as
adjusters by substantive knowledge were excluded based on the results of bivariate analysis.
Ultimately, all variables included in the models, including those identified by bivariate screen-
ing, have been documented as risk factors for adverse birth outcomes and related to MIP.
In order to assess the impact of malaria status at Visit 1 on longitudinal changes in plasma
concentrations of angiogenic and inflammatory proteins across gestation, multiple linear
mixed-effects models were built for each marker using the lme4 package in R [31,32]. This was
performed by adapting the approach used by Romero and colleagues [30] as described by
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Conroy and colleagues [22]. Models were fitted to each angiogenic, inflammatory, or meta-
bolic mediator measured by ELISA/Luminex as a continuous dependent variable. First, a null
model was created for each marker, using the following fixed terms: maternal age, gravidity,
socioeconomic status, education status, BMI and hemoglobin at Visit 1, and an interaction
term between treatment arm and gestational age. Gestational age was shifted to provide a
meaningful intercept, so that the minimum gestational age was zero. A restricted cubic spline
of gestational age (using the rms package in R [33]) was included as a main effect and in inter-
action terms to capture variation across time, with 3 knots placed at the 10th, 50th, and 90th
quantile of gestational age, as suggested by Harrell [34]. All models also included a by-partici-
pant intercept and by-participant slope as random effects. The impact of early malaria on lon-
gitudinal changes in angiogenic and/or inflammatory markers was evaluated in a second
model by adding malaria status by PCR at Visit 1 as a main effect to the null model. A third
model included the interaction between a spline of gestational age and malaria status at Visit 1
to assess the effect of early malaria on mediator concentrations by gestational age. The
Table 1. Clinical characteristics of women based on malaria status.
Characteristics of cohort Malaria negative� Any malaria positive@
Clinical characteristics Total (n)& n (%) or Median [IQR] Total (n)& n (%) or Median [IQR] P value#, $
Study Arm (IPTp) 490 254 (52) 1,138 557 (49) 0.285
Age (years) 490 23 [20–27] 1,138 20 [18–24] <0.001
Primigravid 490 114 (23) 1,138 448 (39) <0.001
Socioeconomic status (tertiles) lowest 489 123 (25) 1,136 418 (37) <0.001
middle 151 (31) 394 (35)
highest 215 (44) 324 (29)
Education status (tertiles) lowest 489 148 (30) 1,136 339 (30) 0.015
middle 244 (50) 633 (56)
highest 97 (20) 164 (14)
BMI at Visit 1 448 23.1 [21.4–25.1] 1,038 22.7 [21.1–24.4] 0.018
Hemoglobin at Visit 1 (g/dL) 448 11.6 [10.7–12.4] 1,038 11.0 [9.9–11.9] <0.001
Gestational age at ultrasound (weeks) 490 20.6 [18.6–22.3] 1,138 20.1 [18.3–22.1] 0.159
Adverse birth outcomes
Gestational age at delivery 446 38.6 [37.6–39.6] 1,090 38.4 [37.1–39.6] 0.042
PTB (<37 weeks) 434 74 (17) 1,072 230 (21) 0.054
Extremely early PTB (<28 weeks) 1 (0.2) 1 (0.1) 0.087
Very PTB (28 to <32 weeks) 1 (0.2) 13 (1.2)
Moderate to late PTB (32 to <37 weeks) 72 (17) 217 (20)
Birth weight (kg) 409 3.0 [2.7–3.3] 1,042 2.9 [2.6–3.2] <0.001
LBW (<2,500 g) 409 32 (8) 1,042 124 (12) 0.024
SGA (<10th percentile) 409 58 (14) 1,042 180 (17) 0.152
Stillbirth or spontaneous abortion 447 12 (2.7) 1,097 19 (1.7) 0.226
�Malaria negative: All PCR assays and placental histology were negative for malaria.
@Malaria positive: At least one PCR test or placental histology was positive for malaria.
#n (%), Chi-square analysis.
$Median [IQR], Mann-Whitney Analysis.
Significant p-values (p< 0.05) are bolded.
&Samples (n) available for each variable for analysis.
Abbreviations: BMI, body mass index; IPTp, intermittent preventive treatment in pregnancy; IQR, interquartile range; LBW, low birth weight; PTB, preterm birth;
SGA, small for gestational age
https://doi.org/10.1371/journal.pmed.1002914.t001
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estimates and standard error are reported for the final model that included malaria status and
the interaction term. The likelihood ratio test was used to compare the 3 models and assess the
impact of malaria status (by PCR) at Visit 1 on model fit. Acknowledging the biases introduced
by the likelihood ratio test, parameters of model fit (i.e., Akaike information criterion [AIC],
Bayesian information criterion [BIC]) are also reported for each of the 3 models. Mediator lev-
els were natural log-transformed for the linear mixed-effects modeling, and residual plots did
not show apparent deviation from normality or homoscedasticity. To account for design of
parent trial and minor longitudinal differences in mediators by treatment arm, treatment
group was included as a covariate in all models. Missing data were excluded from the analyses,
and the percentage of missing data is reported (S2 Table).
Results
Clinical characteristics and malaria status
Of the 1,873 women initially enrolled in the trial [26], 3,386 samples were tested from 1,628
women over 3 study visits as shown in Fig 1. The women included in this analysis had a
median age of 21 years (interquartile range [IQR] 18, 25), 562 (35%) were primigravid, and
811 (50%) were in the IPTp arm. Of the infants, 11% (n = 156/1451) were LBW, 20% (n = 304/
1506) were preterm, and 16% (n = 238/1451) were SGA. Because there were no significant dif-
ferences between treatment arms in the frequency of malaria at any of the 3 visits, placental
malaria, PTB, or SGA, the combined data were analyzed.
Fig 1. Flow chart for patient population. ISTp, intermittent screening and treatment in pregnancy.
https://doi.org/10.1371/journal.pmed.1002914.g001
Early malaria infection and risk of preterm birth
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A total of 70% (n = 1,138) of women had malaria during pregnancy, as determined by at
least one positive PCR test for malaria and/or positive placental histology (Table 1). Malaria-
positive women were more likely to be younger, primigravid, of lower socioeconomic status,
of lower education status, and to deliver at an earlier gestational age with a lower birth weight
(Table 1). There were no significant differences in rates of C-section deliveries between
malaria-positive women or malaria-negative women (3.0% [n = 33] versus 2.5% [n = 11],
p = 0.554). Placental malaria, based on placental histology, was observed in 23% (n = 377;
Table 2). At Visit 1 (enrolment, prior to treatment allocation; 13 to 23 weeks), 40% (n = 649) of
women tested positive for malaria (Table 2). Thirty percent (n = 490) had no evidence of
malaria infection by placental histology and PCR testing at any time during pregnancy.
Malaria infection before 24 weeks gestation was associated with an
increased risk of preterm birth
Women with at least one malaria infection during pregnancy were more likely to deliver a
LBW infant (12% versus 8%, p = 0.024) and trended toward delivering a PTB infant (21% ver-
sus 17%, p = 0.054; Table 1) but were not more likely to deliver an SGA infant than malaria-
negative women (17% versus 14%, p = 0.152; Table 1). Compared with women who were
malaria negative, women who were malaria positive at Visit 1 had a higher frequency of PTB
(24% versus 18%, p = 0.005) corresponding to an adjusted RR (aRR) of 1.30 (95% CI, 1.04–
1.63, p = 0.021; Fig 2). Because some of these women also tested positive for malaria at later
Table 2. Characteristics of malaria infections in the malaria-positive women.
Characteristics Malaria positive&
Episodes of malaria during pregnancy n (% of entire cohort)$
0� 41 (2.5)
1 464 (29)
2 289 (18)
3 154 (9)
4 97 (6)
5 57 (4)
6 23 (1.4)
7 8 (0.5)
8 4 (0.2)
Visit 1 (13 to 23 weeks)#
Malaria positive, peripheral blood 649 (40)
Visit 2 (28 to 33 weeks)#
Malaria positive, peripheral blood 192 (12)
Visit 3 (34 to 36 weeks)#
Malaria positive, peripheral blood 161 (10)
Malaria status at delivery#
Positive malaria, peripheral blood 284 (17)
Positive malaria, placental blood 242 (15)
Placental histology 377 (23)
&Malaria positive: At least one PCR test and/or placental histology was positive for malaria.
$n (%, malaria positive/entire cohort [n = 1,628]).
�These women had placental histology positive for malaria.
#See S2 Table for numbers of missing data.
https://doi.org/10.1371/journal.pmed.1002914.t002
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visits (scheduled or unscheduled), we repeated the analysis on women who only tested positive
for malaria at Visit 1. In this restricted analysis, compared with women who were malaria neg-
ative throughout pregnancy, women with malaria only at the first antenatal visit had an aRR of
1.67 (95% CI, 1.20–2.30, p = 0.002) for PTB (Fig 2).
To confirm the effect of malaria status on gestational age at delivery, we analyzed gesta-
tional age at delivery by quantile regression (S3 Table). This analysis confirmed that malaria
infection early in pregnancy is associated with a reduced gestational age, especially in the
lower quantiles. As would be expected, it also showed a significant association between placen-
tal histopathology and gestational age at delivery in the lowest quantile (S3 Table).
There were no significant increases in risk of SGA or nonviable births in women with
malaria when analyzed based on specific visits, cumulative malaria status, or placental malaria
(p> 0.05).
Malaria infection was associated with altered levels of inflammatory,
metabolic, and angiogenic factors at each visit
At Visit 1, compared with uninfected women, malaria-infected women had significantly
higher levels of CHI3L1, CRP, sICAM-1, IL-18BP, sTNFRII, and sEng and lower levels of Lep-
tin (p� 0.005; Table 3). At Visit 2, malaria-positive women had significantly higher levels of
CRP, IL-18BP, sTNFRII, and sEng (p� 0.005) and lower levels of PlGF and Leptin (p�
0.005); and, at Visit 3, they had significantly higher levels of CRP, IL-18BP, sTNFRII, and sEng
(p� 0.005) and lower levels of PlGF (p� 0.005; Table 3).
Malaria infection before 24 weeks gestation is associated with altered
longitudinal kinetics of angiogenic, metabolic, and inflammatory
mediators over the course of pregnancy
We used linear mixed-effects modeling to assess the kinetics of mediators across pregnancy in
women based on malaria status at Visit 1 (Table 4; S4–S6 Tables), and these kinetics were visu-
ally depicted (Fig 3). This analysis demonstrated that women who were positive for malaria at
Fig 2. aRR of PTB based on malaria status and/or placental histology. Malaria status of women at each Visit 1 (13–23 weeks), Visit 2 (28–33 weeks)
or Visit 3 (34–36 weeks) were assessed. Women who had only a single positive PCR recorded over the course of pregnancy and that positive result was
at Visit 1 were denoted as Only Visit 1: Malaria positive. Log-binomial regression with a log link function was used to calculate the aRR and
corresponding 95% CI. RR was adjusted for treatment arm (ISTp versus IPTp), maternal age, gravidity, socioeconomic status, education status, BMI,
and hemoglobin at Visit 1. aRR, adjusted relative risk; BMI, body mass index; CI, confidence interval; IPTp, intermittent preventive treatment in
pregnancy; ISTp, intermittent screening and treatment in pregnancy; PTB, preterm birth.
https://doi.org/10.1371/journal.pmed.1002914.g002
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Visit 1 had significantly altered kinetics of the inflammatory markers, including CRP (χ2 =
99.0, p< 0.001), CHI3L1 (χ2 = 21.9, p< 0.001), IL18-BP (χ2 = 44.7, p< 0.001), sICAM-1 (χ2 =
40.8, p< 0.001), and sTNFRII (χ2 = 209.2, p< 0.001; Fig 3, Table 4; S4 and S6 Tables) over the
course of pregnancy compared with women who were malaria negative at Visit 1. Altered
kinetics were also observed in women with malaria at Visit 1 for the following angiogenic and
metabolic factors: sEng (χ2 = 38.3, p< 0.001), Angptl3 (χ2 = 13.3, p = 0.001), and Leptin (χ2 =
Table 3. The presence of malaria at each visit is associated with changes in angiogenic, metabolic, and inflamma-
tory mediators.
Analyte by visit Median (IQR) Median (IQR)
Visit 1 (13 to 23 wks) Malaria negative (n = 813) Malaria positive (n = 643) p value#
CHI3L1 (ng/mL) 16.55 (9.44–32.43) 19.68 (11.17–38.71) 0.001
CRP (ug/mL)� 2.45 (1.17–5.23) 5.69 (2.69–13.52) <0.001
sICAM-1 (ng/mL) 197.64 (78.91–447.62) 235.24 (111.02–519.35) 0.003
IL-18 BP (ng/mL) 13.41 (9.53–18.26) 17.67 (12.36–25.76) <0.001
sTNFRII (ng/mL) 2.01 (1.4–2.91) 3.78 (2.22–6.28) <0.001
PlGF (pg/mL) 50.05 (29.64–83.9) 45.22 (23.43–81.69) 0.010
sEng (ng/mL) 2.33 (1.73–2.96) 2.78 (2.02–4.14) <0.001
sFlt-1 (ng/mL) 2.00 (1.31–3.02) 2.15 (1.35–3.16) 0.123
Angptl3 (ng/mL) 15.45 (9.14–24.65) 16.93 (10.4–26.71) 0.017
Leptin (ng/mL) 7.56 (4.42–12.67) 6.53 (3.72–10.89) 0.001
Visit 2 (28 to 33 wks) Malaria negative (n = 863) Malaria positive (n = 188) p value
CHI3L1 (ng/mL) 17.33 (10.85–32.12) 17.67 (9.6–35.13) 0.837
CRP (ug/mL)� 2.22 (0.9–4.58) 4.52 (1.6–11.3) <0.001
sICAM-1 (ng/mL) 222.16 (93.4–464.42) 212.94 (112.54–515.98) 0.417
IL-18 BP (ng/mL) 15.23 (11.93–19.6) 20.97 (15.58–27.76) <0.001
sTNFRII (ng/mL) 2.40 (1.85–3.16) 2.88 (1.85–5.24) <0.001
PlGF (pg/mL) 151.67 (80.02–266.04) 131.3 (55.89–247.82) 0.021
sEng (ng/mL) 2.72 (2.08–3.73) 2.93 (2.2–4.31) 0.005
sFlt-1 (ng/mL) 2.90 (2.01–4.07) 2.94 (2.23–4.07) 0.471
Angptl3 (ng/mL) 20.26 (11.86–31.06) 20.81 (11.89–30.54) 0.868
Leptin (ng/mL) 6.72 (3.68–11.24) 5.27 (3.38–9.32) 0.004
Visit 3 (34 to 36 wks) Malaria negative (n = 627) Malaria positive (n = 157) p value
CHI3L1 (ng/mL) 19.49 (11.45–34.88) 21.28 (12.19–40.21) 0.161
CRP (ug/mL)� 2.48 (1.17–4.73) 4.86 (2.07–14.85) <0.001
sICAM-1 (ng/mL) 244.96 (111.09–521.38) 278.93 (152.87–480.8) 0.164
IL-18 BP (ng/mL) 15.41 (11.71–19.88) 18.91 (14.27–26.07) <0.001
sTNFRII (ng/mL) 2.45 (1.88–3.09) 3.18 (2.22–5.46) <0.001
PlGF (pg/mL) 82.08 (37.21–171.34) 56.55 (21.31–123.54) <0.001
sEng (ng/mL) 3.93 (2.77–5.96) 4.63 (3.07–7.1) 0.004
sFlt-1 (ng/mL) 4.05 (2.79–5.46) 3.92 (3.03–5.16) 0.908
Angptl3 (ng/mL) 24.01 (15.32–34.58) 23.63 (14.28–32.81) 0.494
Leptin (ng/mL) 7.00 (3.87–11.87) 6.56 (3.86–9.81) 0.067
#Mann-Whitney analysis, adjusted p-value for multiple comparisons, significant if p� 0.005 (bolded p-values).
�CRP sample numbers: Visit 1 (782;606), Visit 2 (834; 171), Visit 3 (603;147).
Abbreviations: Angptl3, Angiopoietin-like 3; CHI3L1, Chitinase 3-like protein-1; CRP, C-Reactive Protein; IL-18
BP, Interleukin 18 Binding Protein; IQR, interquartile range; P1GF, placental growth factor; sFlt-1, soluble Fms-like
Tyrosine Kinase-1; sICAM-1, soluble Intercellular Adhesion Molecule-1; sEng, soluble Endoglin; sTNFRII, soluble
Tumor Necrosis Factor receptor II
https://doi.org/10.1371/journal.pmed.1002914.t003
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13.2, p = 0.001; Fig 3, Table 4; S5 and S6 Tables). The longitudinal kinetics of both sFlt-1 and
PlGF were unaffected by malaria status at Visit 1 (p> 0.05; Fig 3, Table 4, S5 and S6 Tables).
When analyzed based on gravidity (S7–S12 Tables), similar associations were observed
between women who were primigravid, except Leptin was no longer significant (p = 0.075),
and for women who were multigravida, except Leptin (p = 0.104) and sEng (p = 0.132) were
no longer significant.
Discussion
This study assessed the longitudinal kinetics of key mediators of angiogenesis, metabolism,
and inflammation over the course of pregnancy in a large cohort of women at risk of P. falcipa-
rum MIP. In these women, malaria infections detected before 24 weeks gestation altered these
tightly regulated pathways that are required for placental function and healthy birth outcomes.
Moreover, we show that malaria infections in early to midpregnancy (<24 weeks of gestation
and before women were receiving malaria chemoprevention) were associated with PTB, a lead-
ing cause of childhood mortality [35], even if there was never another documented malaria
infection during pregnancy. These observations provide insights into the pathobiology of MIP
and suggest early interventions to reduce the burden of MIP may be required to prevent
malaria-associated adverse birth outcomes in sub-Saharan Africa.
The study design and high prevalence of malaria in this cohort of pregnant women enabled
a longitudinal assessment of the impact of MIP on key mediators over pregnancy. Inflamma-
tory responses have previously been investigated in nonpregnant adults and children with
malaria [36–41]; however, there are limited data on these mediators in MIP, especially early in
pregnancy. Here, we provide first evidence that concentrations of sICAM-1, CHI3L1, and IL-
18BP are increased in women with MIP before 24 weeks of gestation. These proteins play a key
role in the interaction between inflammation and vascular function, and alterations in their
Table 4. Random-slope, random intercept linear mixed-effects modeling showed that malaria infection at Visit 1 (13–23 weeks) was associated with changes in
inflammatory and angiogenic mediators across pregnancy. Fixed effects included a spline of gestational age, treatment group, maternal age, gravidity, socioeconomic
status, educational status, BMI, and hemoglobin at Visit 1. Malaria status at Visit 1 (13–23 weeks) was added to the model, and an interaction term for gestational age and
malaria status was added to a third model; then the models were compared (χ2, p value). A restricted cubic spline of gestational age was used as both main effect and in
interaction terms. Extended tables including estimates for all fixed effects and parameters of model fit (AIC, BIC) are available in the supporting information (S4–S6
Tables).
Mediator Number of subjects Number of observations Malaria positive at Visit 1 LR test
Estimate Standard error χ2 p Value
sICAM-1 1,460 3,142 0.344 0.088 40.8 <0.001
CRP 1,394 3,007 1.010 0.123 99.0 <0.001
CHI3L1 1,460 3,142 0.300 0.081 21.9 <0.001
sTNFRII 1,460 3,142 0.954 0.069 209.2 <0.001
IL-18BP 1,460 3,140 0.383 0.053 44.7 <0.001
Angptl3 1,460 3,142 0.200 0.075 13.29 0.001
Leptin 1,460 3,135 -0.062 0.064 13.16 0.001
PlGF 1,460 3,135 -0.116 0.070 2.89 0.236
sFlt-1 1,460 3,135 0.042 0.050 1.09 0.580
sEng 1,460 3,135 0.329 0.049 38.26 <0.001
Significant p-values (p< 0.05) are bolded.
Abbreviations: AIC, Akaike information criterion; Angptl3, Angiopoietin-like 3; BIC, Bayesian information criterion; BMI, body mass index; CHI3L1, Chitinase 3-like
protein-1; CRP, C-Reactive Protein; IL-18BP, Interleukin 18 Binding Protein; LR, likelihood ratio; PlGF, placental growth factor; sEng, soluble Endoglin; sFlt-1, soluble
Fms-like Tyrosine Kinase-1; sICAM-1, soluble Intercellular Adhesion Molecule-1; sTNFRII, soluble Tumor Necrosis Factor receptor II
https://doi.org/10.1371/journal.pmed.1002914.t004
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levels are associated with an increased risk of poor birth outcomes, including PTB [18,42]. We
also show that the inflammatory markers, CRP and sTNFRII, were elevated in MIP, in agree-
ment with previous data [21,43–47]. Tight control of inflammation is required for healthy
pregnancies, especially for proper placentation and fetal development, whereas dysregulated
inflammation is associated with poor placental function and adverse pregnancy outcomes,
including preeclampsia [48–50].
Placental vascular development requires tightly regulated expression of both angiogenic
and anti-angiogenic mediators [51]. Alterations to these highly coordinated pathways can
have a profound impact on placental function, fetal development, and birth outcome
[22,51,52]. Here, we show that concentrations of a key anti-angiogenic factor, sEng, are signifi-
cantly higher in women with MIP, in agreement with previous reports [16,25]. Moreover, we
demonstrate that sEng concentrations remain significantly higher across pregnancy in women
who were malaria positive at their initial visit. Increased concentrations of circulating sEng in
pregnancy have previously been associated with PTB, FGR, and stillbirth [18,22,42,53,54].
Fig 3. Malaria before 24 weeks gestation alters the longitudinal kinetics of angiogenic, inflammatory, and metabolic mediators over the course of
pregnancy. Linear regression lines of best fit with 95% CI are represented on the graph. Malaria positive at Visit 1 (red); malaria negative at Visit 1
(black; 13 to 23 weeks gestation). Angptl3, Angiopoietin-like 3; CHI3L1, Chitinase 3-like protein-1; CI, confidence interval; CRP, C-Reactive Protein;
IL18BP, Interleukin 18 Binding Protein; PlGF, placental growth factor; sEng, soluble Engdolin; sFlt-1, soluble Fms-like Tyrosine Kinase-1; sICAM-1,
soluble Intercellular Adhesion Molecule-1; TNFRII, Tumor Necrosis Factor receptor II.
https://doi.org/10.1371/journal.pmed.1002914.g003
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sFlt-1 is another anti-angiogenic mediator; however, its role in MIP remains unclear. When
measured at antenatal visits across pregnancy in women with MIP, Bostrom and colleagues
showed no significant differences in peripheral levels of sFlt-1 [55], and Ruizendaal and col-
leagues showed a trend towards lower levels of sFlt-1 in women with peripheral malaria in the
second trimester but no difference in sFlt-1 levels in the third trimester or at delivery [43].
Whereas Conroy and colleagues [16] and Muehlenbachs and colleagues [56] reported that
when measured at delivery, women with smear-positive malaria have elevated peripheral and
placental levels of sFlt-1. Our study showed no significant differences in levels of sFlt-1 when
measured at antenatal visits across pregnancy; however, we did not evaluate levels at delivery.
Further studies are required to clarify the role of sFlt-1 in MIP-associated adverse birth
outcomes.
Angptl3 plays a role in both angiogenesis and lipid metabolism [57]. Here, we report that
concentrations of Angptl3 increased over the course of pregnancy and that MIP in the second
trimester altered its longitudinal kinetics. Our findings align with a previous study in Tanzania
in which higher levels of Angptl3 before 23 weeks of pregnancy were associated with increased
risk of PTB [18]. Another central metabolic protein is Leptin, which plays roles in embryonic
implantation, placental endocrine function, fetal development, and immune regulation [58–
60]. In this study, lower levels of Leptin were observed in women with malaria over the course
of pregnancy, consistent with prior findings [43,44,61,62]. Lower Leptin levels have previously
been linked to adverse birth outcomes, including PTB, miscarriage, and intrauterine growth
restriction [18,58,63].
Several of the effector molecules analyzed in this study have pleiotropic effects reflecting
crosstalk between the angiogenic, inflammatory, and metabolic pathways [16,51,57,59,60,64–
71]. This suggests that alterations in one or more of the above mediators may trigger a cascade
of events contributing to placental dysfunction and potentially PTB. Unger and colleagues
demonstrated that malaria-negative women with high levels of sEng, CRP, and sFlt-1 were
more likely to deliver PTB, which they attributed to other inflammatory stimuli, including
infections other than malaria [42]. Several lines of evidence support the hypothesis that there
are common pathways of injury that contribute to altered placental function and adverse birth
outcomes due to differing initiating events, some infectious and some not [18,19]. Our data
suggest that malaria infection prior to 24 weeks is one such modifiable risk factor that is associ-
ated with the alterations of these critical pathways of placental development and function. It is
unknown what the key factors are, and additional mechanistic investigations will be required
to define the mediators playing causal roles in the pathogenesis of adverse birth outcomes and
which are a consequence of these events. Ultimately, a detailed understanding of the critical
drivers of pathobiology may inform pathway-directed interventions to prevent or reduce
adverse birth outcomes associated with MIP [16,24].
In this pregnancy cohort, the prevalence of PTB, as determined by ultrasound dating, was
high at 20%, consistent with previous population estimates for Malawi (16%–18%) [72,73].
Our findings of an increased risk of PTB associated with malaria infection detected at 13 to 23
weeks appear to be in contrast to previous reports, suggesting that malaria infection late in
pregnancy was associated with an increased risk of PTB [10,11]. Although other studies have
shown that malaria infection in the first and/or second trimester is associated with LBW
infants [12,74,75], these studies were largely based on the use of less rigorous methods to deter-
mine gestational age (e.g., Dubowitz, LMP versus ultrasound) and infection status (smears ver-
sus PCR diagnosis). These methods may have limited detection of submicroscopic infections
earlier in pregnancy and enrolment, as well as limitations in discriminating FGR from PTB as
a cause of LBW. This contention is supported by our observation that malaria infection during
the second trimester was significantly associated with PTB but not SGA infants. The use of
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ultrasound in this study improved the accuracy of gestational age dating and, therefore, helped
differentiate between causes of LBW.
This study had a number of strengths, including a prospective design that evaluated over
3,300 samples collected across pregnancy from 1,628 women at high risk of malaria early in
pregnancy. This sample size provided a robust assessment of the concentrations and kinetics
of critical angiogenic, metabolic, and inflammatory factors over the course of pregnancy and
their relationship to MIP. Many previous efforts were conducted as cross-sectional studies
with smaller sample sizes; the longitudinal nature of our study is important given the dynamic
nature and tight regulation of these mediators across pregnancy. Although ultrasound dating
in the first trimester is more accurate, it is difficult to achieve in settings in which women pres-
ent for their first antenatal care often in their second trimester and beyond [27,76]. In Malawi,
over 70% of women present after 16 weeks gestation [77]. As such, the use of second trimester
ultrasound dating is a viable alternative when first trimester ultrasounds are unavailable and is
reasonably accurate [27,76,78]. In our study, ultrasound dating enabled investigation into the
association between MIP and PTB, a relationship that has been more challenging to define
because of difficulties in obtaining reliable estimates of gestational age in low-resource settings.
Despite the size of the cohort, the study was underpowered to assess the impact of malaria on
risk of nonviable births. Further, the majority of malaria cases occurred in midpregnancy, so
robust estimates of the impact of malaria infection occurring later in pregnancy was limited.
Women who had previously taken IPTp were excluded from the study, which may have over-
estimated the prevalence of malaria in this cohort. All women in this study received an inter-
vention, and, therefore, the effects observed may be underestimated for women not receiving
any antimalarials. Additionally, information on other potential infections, other than HIV,
was unavailable in this cohort and may also contribute to changes in these mediators of
interest.
Our findings have implications for current malaria prevention strategies in pregnant
women in high-transmission areas of sub-Saharan Africa. IPTp-SP from 16 weeks of gestation
and insecticide-treated bednets initiated at the first antenatal visit are the current standard of
care. In this study, malaria infection detected between 13 to 23 weeks gestation was already
associated with alterations in angiogenic, metabolic, and inflammatory pathways, and these
changes persisted throughout pregnancy. The risk of PTB remained elevated despite clearance
of infection as determined by PCR. These data indicate that malaria infection frequently
occurs before women present for antenatal care. Moreover, these early infections may play an
important role in the development of inflammatory responses and placental dysfunction, con-
ditions that increase the risk of PTB. WHO recommends initiating IPTp-SP as early as possible
during the second trimester [79]; however, considering that almost half of the women in this
study presented with malaria at enrolment, this strategy is inadequate to protect women from
early malaria infections and an increased risk of PTB. Our findings are supported by Kakura
and colleagues who also showed that over 50% of women had detectable parasites at their first
antenatal visit [80]. Furthermore, several trials investigating strategies to reduce MIP have not
reported a decrease in PTB despite a decreased prevalence of malaria over pregnancy [81–83].
Collectively, these data suggest that intervention strategies will need to be initiated earlier in
pregnancy (i.e., first trimester) in order to protect women from malaria-associated adverse
birth outcomes and to prevent a major cause of infant death.
Although the data from this study suggest that earlier interventions in pregnancy may be
required to prevent adverse birth outcomes, such as PTB, there are currently limited interven-
tions that can be started in the first trimester. SP is currently not recommended for administra-
tion in the first trimester [79]; folate antagonist administration is associated with neural tube
defects because the neural tube closes during the first trimester [84]. Additional clinical trials
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are required to investigate alternative pharmacological therapeutic strategies that can be
administered in the first trimester in highly endemic areas. Furthermore, additional investiga-
tions are required to understand the mechanisms underlying malaria-induced placental dys-
function and adverse birth outcomes, including PTB.
In conclusion, we found that in this cohort that MIP in midpregnancy (13–23 weeks) was
associated with alterations in inflammatory, angiogenic, and metabolic pathways. These infec-
tions were associated with an increased risk of PTB. Collectively, these data support the
hypothesis that MIP early in pregnancy initiates inflammatory responses and altered placental
vascular function that persist throughout pregnancy and contribute to PTB. These findings
suggest that intervention strategies to prevent MIP will be required earlier in pregnancy to pre-
vent placental dysfunction and malaria-associated adverse birth outcomes.
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